Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Biosimilar Candidate GP40141 Found Similar to Romiplostim for Idiopathic Thrombocytopenic Purpura
December 1st 2023The aim of developing GP40141 as a biosimilar is to help reduce the cost of the drug and make treatment more affordable for those with idiopathic thrombocytopenic purpura, according to investigators.
Read More
Study: Income Associated With Cardiologist Care for Those With Heart Failure
December 1st 2023Although involvement of a cardiologist for heart failure has been associated with reduced rates of in-hospital mortality, not all patients see a cardiologist when hospitalized, according to the investigators.
Read More
Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma
November 29th 2023Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.
Read More
FDA Grants Breakthrough Therapy Designation to Epcoritamab for Follicular Lymphoma
November 28th 2023The update followed results from the phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of the drug, including in individuals with relapsed or refractory follicular lymphoma.
Read More
Prior Authorizations Pose Barrier to Access for HIV Preexposure Prophylaxis
November 27th 2023The study authors reported that plans in the South had the highest rates of exclusive PAs for either emtricitabine/tenofovir disoproxil fumarate or emtricitabine/tenofovir alafenamide even if the plan covered both, from 2018 to 2020.
Read More
CDC, FDA Announce 77,000 Additional Doses for Nirsevimab as Infant Treatment of RSV
November 22nd 2023Additional doses for the prophylaxis of respiratory syncytial virus will immediately be distributed to physicians and hospitals through commercial channels and the Vaccines for Children Program.
Read More
Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
November 21st 2023Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.
Read More
Extended-Release Buprenorphine Found Well-Tolerated for Fentanyl Opioid Use Disorder
November 21st 2023Eligible individuals with opioid use disorder using fentanyl received a single 4 mg dose of transmucosal buprenorphine followed by the extended-release buprenorphine 300 mg injection after approximately 1 hour.
Read More